GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Debt-to-Asset
中文

Trinity Biotech (Trinity Biotech) Debt-to-Asset : 1.05 (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Debt-to-Asset?

Trinity Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.81 Mil. Trinity Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $65.21 Mil. Trinity Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $63.60 Mil. Trinity Biotech's debt to asset for the quarter that ended in Sep. 2023 was 1.05.


Trinity Biotech Debt-to-Asset Historical Data

The historical data trend for Trinity Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Debt-to-Asset Chart

Trinity Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.78 0.80 0.83 0.78

Trinity Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.78 0.84 0.94 1.05

Competitive Comparison of Trinity Biotech's Debt-to-Asset

For the Diagnostics & Research subindustry, Trinity Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Debt-to-Asset falls into.



Trinity Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Trinity Biotech's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.886 + 70.314) / 92.104
=0.78

Trinity Biotech's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trinity Biotech  (NAS:TRIB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Trinity Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.